1 Treatment planning for photodynamic therapy of abscess cavities using patient-specific

2 optical properties measured prior to illumination

- 3 Short title: Treatment planning for abscess PDT
- 4 Zihao Li¹, Md Nafiz Hannan², Ashwani K. Sharma³, Timothy M. Baran^{1,3,4,*}
- ⁵ ¹ Department of Biomedical Engineering, University of Rochester, Rochester, NY
- 6 ² Department of Physics and Astronomy, University of Rochester, Rochester, NY
- ³ Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY
- 8 ⁴ The Institute of Optics, University of Rochester, Rochester, NY
- 9 * Corresponding author:
- 10 Timothy M. Baran (<u>timothy.baran@rochester.edu</u>)
- 11 601 Elmwood Ave., Box 648
- 12 Rochester, NY 14642

13 Abstract

Background: Photodynamic therapy (PDT) is an effective antimicrobial therapy that we used to treat human abscess cavities in a recently completed Phase 1 clinical trial. This trial included pre-PDT measurements of abscess optical properties, which affect the expected light dose to the abscess wall and eventual PDT response.

18 **Purpose:** The objective of this study was to simulate PDT treatment planning for the 13

19 subjects that received optical spectroscopy prior to clinical abscess PDT. Our goal was to

20 determine the impact of these measured optical properties on our ability to achieve fluence rate

21 targets in 95% of the abscess wall.

22 Methods: During a Phase 1 clinical trial, 13 subjects received diffuse reflectance spectroscopy

23 prior to PDT in order to determine the optical properties of their abscess wall. Retrospective

treatment plans seeking to achieve fluence rate targets in 95% of the abscess wall were

evaluated for all subjects for 3 conditions: (1) at the laser power delivered clinically with

assumed optical properties, (2) at the laser power delivered clinically with measured optical

27 properties, and (3) with patient-specific treatment planning using these measured optical

28 properties. Factors modified in treatment planning included delivered laser power and intra-

29 cavity Intralipid (scatterer) concentration. The effects of laser fiber type were also simulated.

Results: Using a flat-cleaved laser fiber, the proportion of subjects that achieved 95% abscess 30 wall coverage decreased significantly when incorporating measured optical properties for both 31 the 4 mW/cm² (92% vs. 38%, p=0.01) and 20 mW/cm² (62% vs. 15%, p=0.04) fluence rate 32 thresholds. However, when measured optical properties were incorporated into treatment 33 planning, a fluence rate of 4 mW/cm² was achieved in 95% of the abscess wall for all cases. In 34 treatment planning, the optimal Intralipid concentration across subjects was found to be 0.14 ± 35 36 0.09% and the optimal laser power varied from that delivered clinically but with no clear trend 37 (p=0.79). The required laser power to achieve 4 mW/cm² in 95% of the abscess wall was 38 significantly correlated with measured μ_a at the abscess wall (p=0.7, p=0.008), but not abscess 39 surface area (p=0.2, p=0.53). When using spherical diffuser fibers as the illumination source, 40 the optimal intralipid concentration decreased to $0.028 \pm 0.026\%$ (p=0.0005), and the required 41 laser power decreased also (p=0.0002), compared to flat cleaved fibers. If the intra-cavity lipid emulsion (Intralipid) was replaced with a non-scattering fluid, all subjects could achieve the 4 42 mW/cm² fluence rate threshold in 95% of the abscess wall using a spherical diffuser, while only 43 69% of subjects could reach the same criterion using a flat cleaved fiber. 44

- 45 **Conclusions:** The range of optical properties measured in human abscesses reduced
- 46 coverage of the abscess wall at desirable fluence rates. Patient-specific treatment planning
- 47 including these measured optical properties could bring the coverage back to desirable levels by
- 48 altering the Intralipid concentration and delivered optical power. These results motivate a future
- 49 Phase 2 clinical trial to directly compare the efficacy of patient-specific-treatment planning with
- 50 fixed doses of Intralipid and light.
- Keywords: photodynamic therapy, abscess, methylene blue, Monte Carlo simulation, clinical
 trial
- 53 Clinical Trial Registration: The parent clinical trial from which these data were acquired is
- registered on ClinicalTrials.gov as "Safety and Feasibility Study of Methylene Blue
- 55 Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities," with ClinicalTrials.gov
- identifier NCT02240498.

57 Introduction

58 An abscess consists of a fibrous pseudo-capsule surrounding a localized collection of bacteria. 59 purulent fluid, and necrotic tissue¹. Abscesses form as a result of the immune and inflammatory response to an acute infection, leading to nausea, pain, and high morbidity and mortality if 60 untreated². While the application of image-guided percutaneous abscess drainage has become 61 62 the standard of care, response rate can be highly variable between subjects³⁻⁵. Additionally, 63 there is concern that the antibiotics used alongside drainage will become less effective in the 64 future, as antibiotic-resistant bacteria become increasingly common. We and others have directly observed the presence of multidrug-resistant bacteria in fluid aspirated from human 65

66 abscesses⁶⁻⁸. It is therefore apparent that alternative treatment strategies are necessary,

67 particularly for antibiotic-resistant strains.

68 Photodynamic therapy (PDT), which generates cytotoxic reactive oxygen species via light 69 activation of drugs known as photosensitizers, may represent an ideal candidate treatment. PDT 70 is a highly effective antimicrobial therapy that maintains efficacy against antibiotic resistant 71 bacteria⁹, and can additionally improve susceptibility to antibiotics¹⁰. Based on encouraging pre-72 clinical results showing that PDT with methylene blue (MB) is efficacious against multiple 73 bacteria typically found in abscesses^{6,11,12}, we initiated a Phase 1 clinical trial investigating the 74 safety and feasibility of MB-PDT at the time of abscess drainage (ClinicalTrials.gov identifier: 75 NCT02240498). We found that MB-PDT was safe, with no study-related adverse events observed⁸. Additionally, preliminary analysis suggests that symptom resolution was faster and 76 77 drainage catheter discharge was reduced in subjects receiving higher fluence. This clinical study used a uniform MB concentration of 1 mg/mL (0.1%) across subjects and the optical 78 79 power delivered was based purely upon abscess geometry, rather than measured optical 80 properties. During delivery of treatment light, each abscess was filled with a uniform 1% concentration of lipid emulsion in order to homogenize the light dose at the abscess wall 81 through scattering. This scattering is critical to light delivery, as abscess morphology can be 82 83 highly heterogeneous.

While we based the optical power delivered clinically on irradiance values that were efficacious *in vitro*^{6,12}, the absorbed light dose is of course dependent upon the optical properties
(absorption and scattering) of the target tissue. Multiple studies have shown that incorporation
of patient-specific optical properties into PDT treatment planning results in improved coverage
of the target region¹³⁻¹⁵. This is particularly true for the case of hollow cavities^{16,17}, where the
integrating sphere effect can dramatically increase fluence at the cavity boundary¹⁸. Lilge *et al*,

- 90 for example, showed that this integrating sphere effect leads to a multiplicative factor in fluence
- ⁹¹ rate, which is patient-specific and highly dependent on optical properties¹⁹. We have previously
- 92 looked at simulated PDT of abscess cavities using our Monte Carlo simulation package^{20,21}. We
- found that the ability to deliver an efficacious light dose, and the optical power required to do so,
- 94 are highly dependent upon the optical properties at the abscess wall.
- 95 Whereas prior abscess treatment planning studies utilized assumed optical properties^{20,21}, we
- have now measured the optical properties of 13 human abscesses immediately prior to PDT
- 97 using a spatially-resolved diffuse reflectance spectroscopy system^{22,23}. These measurements
- 98 were performed before and after methylene blue administration, in order to capture bulk
- 99 abscess wall optical properties and MB uptake. Using these pre-PDT optical property
- 100 measurements and pre-procedure CT imaging, it is now possible to generate patient-specific
- 101 treatment plans for subjects that received PDT of their abscess.
- 102 In this study, we describe the generation of patient-specific treatment plans based on pre-
- 103 procedure CT imaging and intra-procedure measurement of optical properties. Specifically, we
- investigate the effects of measured optical properties on the delivered light dose, and determine
- 105 whether patient-specific treatment planning can improve dose volume histograms in the
- presence of high abscess wall absorption. Further, we explore the impact of treatment fiber type
- and elimination of the intra-cavity lipid emulsion. We hypothesize that patient-specific treatment
- planning will increase the percentage of the abscess wall that achieves a target fluence rate,
- and that treatment planning will aid in optimization of MB and lipid emulsion concentrations for
- 110 future studies.

111 Methods

112 <u>Study participants and regulatory approval</u>

- 113 Research subjects were part of a Phase 1 clinical trial examining the safety and efficacy of
- 114 methylene blue (MB) mediated photodynamic therapy (PDT) delivered at the time of
- percutaneous abscess drainage. The full details and results of this clinical trial are described
- elsewhere⁸. As part of this Phase 1 trial, 13 subjects received diffuse reflectance spectroscopy
- prior to MB-PDT in order to determine the optical properties of their abscess, as described
- below. The present study focuses on the examination of treatment planning for these 13
- subjects, including patient-specific optical properties and pre-procedure CT imaging.

- 120 Human data were collected as part of a Phase 1 clinical trial, which was approved by the
- 121 Research Subjects Review Board at the University of Rochester Medical Center (IRB protocol
- number: STUDY00000488). This clinical trial was registered on ClinicalTrials.gov
- 123 (ClinicalTrials.gov identifier: NCT02240498). All subjects provided written informed consent.

124 Optical spectroscopy data

125 As part of the Phase 1 clinical trial, subjects first received standard of care image-guided

- 126 percutaneous abscess drainage. Following this, an initial diffuse reflectance spectroscopy
- measurement of the abscess wall was made using a custom fiber-optic probe and diffuse
- reflectance spectroscopy system. These components, as well as the Monte Carlo lookup table
- approach for optical property recovery, were previously described by Bridger *et al*²⁴. A full
- description of the clinical measurement protocol is provided elsewhere^{22,23}. This pre-MB
- 131 measurement represents the native optical properties of the abscess wall.
- 132 Following the initial measurement, MB was instilled into the cavity at a concentration of 1 mg/mL
- and allowed to incubate for 10 minutes. The cavity was then rinsed with sterile saline, and
- 134 diffuse reflectance measurements were repeated to quantify abscess wall optical properties
- including the effects of MB absorption. Optical properties extracted from these post-MB
- measurements are the ones used below for the layer representing MB uptake by bacteria and
- 137 diffusion into tissue.
- 138 Full details on abscess wall optical properties and MB uptake are described elsewhere by
- 139 Hannan et al^{22,23}. Here, we focus on the effects of these extracted optical properties on patient-
- specific treatment planning to optimize light delivery to individual abscess cavities.
- 141 Pre-procedure imaging and segmentation

142 As part of their standard of care, all subjects received pre-procedure CT imaging no more than 7 days prior to image-guided percutaneous abscess drainage. These images were downloaded in 143 144 a de-identified fashion from the picture archiving and communication system (PACS) at the University of Rochester Medical Center, and stored on a password-protected, encrypted 145 146 workstation. Abscess location was confirmed on imaging by the study doctor (A.K.S.). Each set of CT images was then manually segmented by a member of the study team using Amira 147 148 (Amira 3D v2022.1, ThermoFisher Scientific, Waltham, MA). This was done individually for each 149 axial slice, with the abscess defined as a region of low density surrounded by a highly

enhancing rim. Segmented abscesses were exported as DICOM files for inclusion in thetreatment planning software described below.

152 <u>Treatment planning software</u>

Measured human optical properties and corresponding segmented CT images were imported into our treatment planning software^{20,21}, which is based upon our previously described Monte Carlo package²⁵. This software represents patient anatomy with cuboid voxels, with each voxel being assigned corresponding optical properties. Here, segmented images were represented in two ways:

- 1) Divided into four regions: the abscess wall, surrounding tissue, inside the abscess, 158 159 and a boundary layer. The abscess wall, consisting of a 200 µm thick layer 160 immediately surrounding the abscess, was assigned optical properties corresponding to post-MB spectroscopy. The thickness of this layer was based upon reports 161 162 showing similar diffusion of MB into various tissue types after application at the surface²⁶⁻²⁹. The surrounding tissue was set to pre-MB optical properties. This was 163 meant to represent MB uptake by bacterial biofilms and the diffusion of MB into the 164 abscess wall, rather than assuming homogeneous distribution of MB throughout the 165 166 abscess wall and surrounding tissue.
- 167 2) Divided into three regions: a combined region representing the abscess wall and 168 surrounding tissue, inside the abscess, and a boundary layer. This is the approach 169 used in previous reports by Baran *et al*²⁰ and Li *et al*²¹. In this case, optical properties 170 of the abscess wall and surrounding tissue were both assigned the values measured 171 in post-MB spectroscopy measurements.
- The illumination sources simulated were physically accurate models of either the flat-cleaved optical fiber used clinically or a spherical diffusing fiber with an outside diameter of 2 mm. In both cases, the distal end of the fiber was positioned at the center of mass of the abscess cavity, and a fluence rate of 1 mW was delivered by simulation of 10⁷ photon packets. Output fluence rate maps were scaled linearly to simulate higher delivered optical power, with a maximum value of 10,000 mW. All simulations were performed using a Quadro RTX 6000 graphics processing unit (NVIDIA Corporation, Santa Clara, CA).
- 179 Simulation conditions

180 For both flat-cleaved and spherical sources, we simulated three conditions:

- 181 1) Assumed treatment absorption (μ_a) and scattering (μ_s) coefficients for the abscess wall 182 were set to the assumed values of $\mu_a=0.2 \text{ cm}^{-1}$ and $\mu_s=100 \text{ cm}^{-1}$. The lipid emulsion 183 concentration was fixed at 1%, and the delivered laser power was set to that delivered 184 clinically for each subject. This case was meant to represent the dose we assumed was 185 delivered clinically, which did not include patient-specific optical properties.
- 2) Delivered treatment with measured optical properties $-\mu_a$ and μ_s were set to the optical properties measured for each individual subject, while the lipid emulsion concentration and laser power were fixed at the values used clinically. This case represents a simulation of the dose delivered clinically.
- 3) Treatment planning with measured optical properties μ_a and μ_s were set to the optical properties measured for each individual subject, and the lipid emulsion concentration and delivered laser power were optimized as described in the previous section. This
- and delivered laser power were optimized as described in the previous section. This
- case represents the treatment plan that would have been utilized if the treatment
- 194 protocol were able to be modified on a patient to patient basis.
- 195 For the optimized treatment plan case, we simulated lipid emulsion concentrations ranging from
- 196 0-1%. The concentration used clinically was 1%, and we previously found that lower
- 197 concentrations were optimal in a retrospective simulation study²¹. The assumed values of
- 198 $\mu_a=0.2 \text{ cm}^{-1}$ and $\mu_s=100 \text{ cm}^{-1}$ were based upon values reported for tissues in the peritoneal
- 199 cavity³⁰. Scattering anisotropy was set to 0.7 inside the abscess, corresponding to the value for
- 200 Intralipid at 665 nm³¹, and 0.9 in the abscess wall and surrounding tissue.
- 201 In all cases, the goal was to determine the delivered optical power (threshold optical power) and
- lipid emulsion concentration necessary to achieve a desired fluence rate of 4 mW/cm² or 20
- 203 mW/cm² in 95% of the abscess wall, while limiting the portion of the wall that receives a fluence
- rate of 400 mW/cm² to less than 5%. The 4 mw/cm² target is based upon an efficacious pre-
- 205 clinical condition^{6,12}, while the 20 mW/cm² target is the target fluence rate used clinically⁸ to
- account for the more demanding *in vivo* scenario. The final treatment plan was determined by
- the lipid emulsion concentration that minimized the threshold optical power.

208 <u>Statistical analysis</u>

- 209 For each of the simulation conditions described above, the following endpoints were calculated:
- 210 (1) percentage of the abscess wall receiving at least 4 mW/cm², (2) percentage of the abscess
- wall receiving at least 20 mW/cm², (3) percentage of the abscess wall receiving at least 400
- 212 mW/cm², and (4) delivered optical power required to achieve the threshold fluence rates of 4

and 20 mW/cm². Comparison of these between treatment planning conditions was performed

with the Wilcoxon test. Differences in the proportions of subjects that achieved the desired 95%

abscess wall coverage at a given fluence rate were compared using Fisher's exact test.

216 Correlation between endpoints and abscess characteristics were calculated using the

217 Spearman correlation coefficient. Statistical analysis was performed in GraphPad Prism (v9,

GraphPad Software, Inc., Boston, MA) and MATLAB (R2022b, The Mathworks, Inc., Natick,

219 MA).

220 Results

221 Representative case

222 A representative case is shown in Figure 1. A single slice of the segmented CT scan is shown in 223 Figure 1a, and a rendering of the full segmentation is shown in Figure 1b. For this particular 224 subject, optical properties at the treatment wavelength of 665 nm were found to be $\mu_a = 0.08$ cm⁻ ¹ and $\mu_s' = 4.8$ cm⁻¹ prior to MB administration, and $\mu_a = 49.4$ cm⁻¹ and $\mu_s' = 3.0$ cm⁻¹ following 225 226 MB administration. For the 528 mW delivered clinically and the clinically deployed 1% Intralipid 227 concentration, this resulted in 49.4% of the abscess wall achieving a fluence rate of 4 mW/cm² with a flat-cleaved fiber. Simulations were then run for Intralipid concentrations ranging from 0-228 1% Intralipid, as described above. As shown in Figure 1c, the optimal Intralipid concentration 229 was found to be 0.083%, with a corresponding optical power of 3914 mW. As shown in Figure 230 1d, this combination resulted in 95% of the abscess wall achieving the fluence rate target of 4 231 232 mW/cm², while only 1.9% experienced a fluence rate of at least 400 mW/cm².



233

Figure 1. (a) Pre-procedure Computed Tomography (CT) image for a representative subject. The margin of the segmented abscess area is shown in light blue. (b) Segmented abscess rendered in three dimensions (3D) for the same individual. (c) Threshold optical power as a function of Intralipid concentration inside the abscess. The intersection of the red horizontal and vertical dashed lines indicates the optimal Intralipid concentration and corresponding optimal optical power for this subject after treatment planning. (d) Dose volume histogram representing coverage of the abscess wall as a function of fluence rate for the three simulated conditions.

241 Treatment planning for flat-cleaved optical fibers

Across all 13 subjects, the target fluence rate of 4 mW/cm² was reached in 95% of the abscess wall using assumed optical properties ($\mu_a=0.2 \text{ cm}^{-1}$, $\mu_s'=10 \text{ cm}^{-1}$) and the clinically delivered laser powers in all but one subject (Figure 2a,b). When measured optical properties were simulated with 1% Intralipid and the laser powers delivered clinically, abscess wall coverage at 4 mW/cm² decreased significantly (p=0.005, Figure 2a,b), with only 5 subjects attaining the desired 95% coverage. However, when measured optical properties were incorporated into treatment planning (TP), a fluence rate of 4 mW/cm² was achieved in 95% of the abscess wall

- for all cases. Further, treatment planning decreased the portion of the abscess wall receiving
- fluence rates exceeding 400 mW/cm² (Figure 2e), and reduced the number of subjects expected
- to experience this high fluence rate in greater than 5% of the abscess wall.





Figure 2. Percentage of the abscess wall that received a fluence rate above (a) 4 mW/cm² or (c) 20
mW/cm² under assumed, measured, and treatment planning cases for all 13 subjects. Each color
represents an individual subject. Corresponding means and standard deviations across subjects are
included for the (c) 4 mW/cm² and (d) 20 mW/cm² cases. Percentage of the abscess wall that received a
fluence rate above 400 mW/cm² for these three cases at thresholds of (e) 4 mW/cm² and (f) 20 mW/cm².
* p<0.05 ** p<0.01

259 This treatment planning improvement was enabled by a reduction in Intralipid concentration 260 relative to the 1% concentration deployed clinically and changes in delivered laser optical 261 power. The mean optimal Intralipid concentration across subjects, determined using the method shown in Figure 1c, was found to be $0.14 \pm 0.09\%$ with a range of 0-0.4%. As seen in Figure 3, 262 263 the optimal laser power was typically different from that delivered clinically, with some cases requiring greater laser power than was used clinically and some requiring less. There was a 264 265 slight increase in threshold optical power for treatment planning relative to clinical values (Figure 3), although this difference was not significant (p=0.79). 266





268 Figure 3. (a) Comparison of the optical power that was delivered clinically and optimal optical power

269 determined by treatment planning for all 13 subjects. Each color represents an individual subject. (b)

270 Corresponding means and standard deviations across subjects.

271 We found that the required laser power to achieve 4 mW/cm² in 95% of the abscess wall was

- significantly correlated with measured μ_a at the abscess wall (ρ =0.7, p=0.008; Figure 4a).
- 273 However, this required power was not significantly correlated with abscess surface area (p=0.2,
- p=0.53; Figure 4b). This indicates that the effects of abscess wall optical properties on required
- illumination power are more pronounced than the effects of abscess size.





Figure 4. Relationship between optical power required to achieve a fluence rate of 4 mW/cm² in 95% of the abscess wall after treatment planning and (a) abscess wall μ_a , or (b) abscess surface area, using flat cleaved fiber.

280 Similar trends were seen for the 20 mW/cm² fluence rate target. As with the 4 mW/cm²

condition, there was a significant decrease in the number of subjects attaining 95% coverage

when applying measured optical properties and using the laser powers delivered clinically

(p=0.008, Figure 2c,d). However, the number of cases where 95% coverage was not attainable

for both assumed and measured optical properties increased compared to the 4 mW/cm² case

(Figure 2c). Additionally, there were three subjects for which 95% coverage at 20 mW/cm² could

286 not be achieved with treatment planning.

287 Treatment planning for spherical diffusers

In addition to performing treatment planning for the flat-cleaved optical fibers used to deliver 288 289 laser illumination clinically, we also examined the use of spherical diffusers for light delivery. Similar trends were observed, with lower coverage of the abscess wall at a specific fluence rate 290 threshold when measured optical properties were simulated, relative to assumed optical 291 292 properties. Additionally, after treatment planning the 4 mW/cm² and 20 mW/cm² fluence rate 293 thresholds were achievable in 95% of the abscess wall for all cases. However, the spherical 294 diffuser case required lower optical power and had a lower optimal Intralipid concentration 295 compared to the flat-cleaved fiber results (Figure 5). The optimal Intralipid concentration 296 decreased significantly from $0.14 \pm 0.09\%$ to $0.028 \pm 0.026\%$ (p=0.0005, Figure 5a,c), and the 297 required laser power decreased significantly from the flat-cleaved case (p=0.0002, Figure 5b.d).



298

Figure 5. Comparison between flat-cleaved and spherical diffuser fibers for (a) optimal Intralipid
 concentration and (b) required optical power after treatment planning. Corresponding means and
 standard deviations are included for (c) optimal Intralipid concentration and (d) required optical power. ***
 p<0.001

303 Effects of eliminating intra-cavity lipid emulsion

While our clinical study included 1% Intralipid within the abscess cavity during illumination and 304 305 we have found that a non-zero Intralipid concentration is optimal for both flat-cleaved and spherical diffuser fibers, we also simulated the case of 0% Intralipid within the cavity. This 306 307 represents the case where a non-scattering index-matching fluid is infused into the cavity. 308 Across all 13 subjects, 69% of subjects could reach the 4 mW/cm² fluence rate threshold in 95% of the abscess wall after treatment planning using a flat cleaved fiber, while all subjects could 309 310 achieve the same criterion using a spherical diffuser. As expected, these results were more favorable for the spherical diffuser (Figure 6), as the flat-cleaved fiber requires intra-cavity 311

- 312 scattering to reduce the forward-peaked nature of light emitted from the fiber. For flat-cleaved
- fibers, a greater laser power was typically required to achieve the fluence rate target, relative to
- 314 conditions including intra-cavity scattering. For spherical diffuser fibers, the required optical
- power was decreased relative to conditions including scattering (p=0.004).





Figure 6. (a) Comparison of threshold optical power after treatment planning between flat cleaved fibers
 and spherical diffuser fibers for the case of 0% Intralipid concentration with (b) corresponding means and
 standard deviations across subjects. ** p<0.01

320 Assumption of post-MB optical properties

321 All prior results reported here simulated the effects of MB penetration into the abscess wall by assigning optical properties measured after MB instillation and aspiration to a 200 µm thick layer 322 at the abscess wall. Surrounding tissue optical properties were set to those measured prior to 323 the administration of MB. This was meant to simulate the relatively shallow penetration of MB 324 into tissue observed in prior studies²⁶⁻²⁹. To examine the effects of this assumption, we also 325 326 simulated an artificial condition where optical properties measured post-MB were assigned to 327 the abscess wall and surrounding tissue. As would be expected, abscess wall coverage 328 decreased markedly relative to the 200 µm layer case. Further, 95% coverage of the abscess 329 wall could only be achieved in 31% of cases for the 4 mW/cm² threshold as opposed to 100% in 330 the 200 µm layer case.

331 Discussion

In this study, we found that simulation of PDT of deep tissue abscesses with optical properties

333 measured in treated human subjects reduced the proportion of the abscess wall attaining a

334 given fluence rate target, relative to assumed optical properties. However, by applying patient-335 specific treatment planning using these measured optical properties and modifying the Intralipid 336 concentration present within the abscess during PDT and the delivered laser power, the desired 95% coverage of the abscess wall could be recovered. This was true for both the clinically 337 338 utilized flat-cleaved optical fibers and spherical diffuser fibers, with spherical fibers potentially allowing for lower laser power and reduced Intralipid concentration. These results motivate the 339 340 prospective application of patient-specific treatment planning in future clinical trials of PDT for treatment of abscesses, and highlight the importance of optical property measurements prior to 341 342 PDT.

343 We have previously shown that patient-specific treatment planning incorporating knowledge of

optical properties improved eligibility for abscess PDT in a retrospective population using

345 assumed ranges of tissue absorption and scattering²¹. Here, we demonstrated similar

346 improvements using measured optical properties from subjects that received PDT at our

institution. Other groups have also investigated dosimetry and treatment planning for PDT in

hollow cavities, including for the bladder¹⁹, oropharynx/nasopharynx^{17,32-34}, and pleural

349 cavity^{35,36}. Of note, many of these prior studies did not incorporate measured optical properties

350 for individual patients, but instead either used assumed values or required insertion of separate

351 fibers for dosimetry. This study therefore represents a step forward in patient-specific treatment

planning for PDT of hollow cavities, including the effects of highly variable abscess wall opticalproperties and MB uptake.

354 While flat-cleaved optical fibers were used in the clinical setting for the subjects described here, we also simulated spherical diffuser fibers. We found that spherical diffusers allowed for lower 355 356 laser power and lower Intralipid concentration to achieve the same coverage as flat-cleaved 357 fibers. However, the main disadvantage of spherical diffusers is their reduced optical power threshold compared to flat-cleaved fibers. For example, the Medlight spherical diffuser (SD200, 358 359 Medlight SA, Ecublens, Switzerland) can only handle an input optical power of 3 W in water or 1 360 W in air. For the abscesses treated here, the optical power delivered clinically was as high as 361 1571 mW. Anticipating treatment of larger abscesses in future studies, we are planning to utilize 362 a laser system with output optical power as high as 10 W. These Medlight fibers would therefore 363 be insufficient. However, alternative spherical diffusers, such as the Luminous Spherical 364 Diffuser (Schott AG, Mainz, Germany), are rated for optical powers as high as 20 W. In addition 365 to their higher power transmission capabilities, there is also the possibility to use flat-cleaved fibers for quantitative optical spectroscopy³⁷. In this way, the additional fiber optic probe 366

367 currently required could be eliminated in favor of an approach that uses the treatment fiber for

368 both low power optical property measurement and delivery of high power treatment light.

369 Validation of this approach is currently ongoing.

370 Based upon the findings reported here, the lipid emulsion concentration can clearly be lowered 371 in future studies. The 1% lipid emulsion concentration used in the clinical study was based upon 372 an apparent improvement in fluence rate distribution for higher MB concentrations at higher lipid emulsion concentration²⁰. However, this finding has not been replicated here or in a prior 373 374 simulation study²¹. The optimal lipid concentration was found to be $0.14 \pm 0.09\%$ for all subjects examined here, and 0-0.25% in a prior simulation study²¹. As other investigators have also 375 376 found that lower intra-cavity lipid concentrations are most efficient for PDT of hollow cavities such as the bladder¹⁹, this concentration will likely be reduced in future clinical studies. Similarly, 377 the MB concentration used clinically was likely too high, as evidenced by the large values of 378 379 absorption at 665 nm. Further justification for use of lower MB concentrations is discussed in 380 detail by Hannan et al²³.

381 The exact effects of MB concentration are also dependent upon the penetration of MB into the 382 target region during the drug-light interval. As we have shown here, simulation of a thin layer representing MB penetration results in a much larger proportion of subjects being eligible for 383 384 PDT. However, the penetration depth assumed here is based upon reports in other tissue types for MB²⁶⁻²⁹, rather than those determined directly in abscesses. This motivates direct 385 measurement of MB depth penetration into abscess tissue. This would be difficult or impossible 386 in human subjects, as any damage to the abscess wall could result in abscess rupture and 387 sepsis. However, animal models of abscess formation do exist in rabbits³⁸ and sheep³⁹. These 388 389 model systems could be used to quantify MB depth penetration, similarly to what has been done for other photosensitizers in various sites⁴⁰⁻⁴². 390

Some limitations are acknowledged in the execution of this study. These results are derived 391 392 from a relatively small sample (n=13), so there is potential for selection bias. Since optical 393 properties were only measured at a single location, we also make assumptions on homogeneity 394 of optical properties. Tissue optical properties can be heterogeneous within a given region, and 395 this heterogeneity can result in changes in absorbed light dose⁴³. As our simulation framework can incorporate voxel-specific optical properties, future studies will focus on methods for 396 397 mapping of heterogeneous optical properties and their effects on treatment planning. In this 398 study, we also examined the effects of MB depth penetration on treatment planning. As 399 described above, we do not have data on the penetration of MB into abscess tissue over the 10 400 minute drug-light interval employed in our clinical study. Inaccuracy in MB penetration depth 401 could therefore affect the treatment planning results reported here. Finally, abscess morphology 402 was based upon pre-procedure CT imaging. For the subjects described here, the interval between pre-procedure imaging and treatment varied from 0-7 days. It is therefore possible that 403 404 abscess shape was slightly different at the time of PDT. This motivates utilization of CT imaging 405 immediately prior to PDT, in order to capture accurate abscess morphology. This could be 406 facilitated by real-time abscess segmentation, which has been demonstrated for orbital 407 abscesses⁴⁴.

408 Conclusions

409 We determined that the ranges of optical properties measured in human abscesses result in

- 410 decreased coverage of the abscess wall at a desired fluence rate for PDT. However, inclusion
- 411 of these measured optical properties into patient-specific treatment planning returned delivered

fluence rates to the desired levels by modification of intra-cavity Intralipid concentration and

- 413 delivered laser power.
- These findings motivate the performance of patient-specific treatment planning prospectively in
- future patients receiving PDT. It is anticipated that this will result in improved coverage of the
- abscess wall at an efficacious fluence rate, which will improve response to PDT and reduce
- negative clinical outcomes. In order to test this, we are currently planning a Phase 2 clinical trial
- that will directly compare PDT efficacy between a fixed light dose and patient-specific treatment
- 419 planning.

420 Acknowledgments

- 421 The authors would like to thank Dr. Joan Adamo for regulatory support. This work was funded
- 422 by grant EB029921 from the National Institutes of Health.

423 Conflict of Interest Statement

424 The authors have no relevant conflicts of interest to disclose.

425

426 References

- Kobayashi SD, Malachowa N, DeLeo FR. Pathogenesis of *Stapylococcus aureus* abscesses. *Am J Pathol.* 2015;185:1518-1527.
- Men S, Akhan O, Köroğlu M. Percutaneous drainage of abdominal abscess. *Eur J Radiol.* 2002;43:204-218.
- 431 3. vanSonnenberg E, Wittich GR, Goodacre BW, Casola G, D'Agostino HB. Percutaneous abscess
 432 drainage: Update. *World J Surg.* 2001;25:362-372.
- 4. Gee MS, Kim JY, Gervais DA, Hahn PF, Mueller PR. Management of abdominal and pelvic
 434 abscesses that persist despite satisfactory percutaneous drainage catheter placement. *AJR Am J*435 *Roentgenol.* 2010;194:815-820.
- 436 5. Gervais DA, Ho C-H, O'Neill MJ, Arellano RS, Hahn PF, Mueller PR. Recurrent abdominal and
 437 pelvic abscesses: Incidence, results of repeated percutaneous drainage, and underlying causes in
 438 956 drainages. *AJR Am J Roentgenol*. 2004;182:463-466.
- 439 6. Haidaris CG, Foster TH, Waldman DL, Mathes EJ, McNamara J, Curran T. Effective photodynamic
 440 therapy against microbial populations in human deep tissue abscess aspirates. *Lasers Surg Med.*441 2013;45:509-516.
- 4427.Mezhir JJ, Fong Y, Jacks LM, et al. Current management of pyogenic liver abscess: Surgery is now443second-line treatment. J Am Coll Surg. 2010;210:975-983.
- 4448.Baran TM, Bass DA, Christensen L, et al. Photodynamic therapy is a safe and feasible adjunct to445percutaneous drainage of deep tissue abscesses: Results of a first in humans Phase 1 clinical446trial. medRxiv. 2023;2023.10.16.23297086.
- 447 9. Hamblin MR, Hasan T. Photodynamic therapy: A new antimicrobial approach to infectious
 448 disease? *Photochem Photobiol Sci.* 2004;3:436-450.
- Feng Y, Coradi Tonon C, Ashraf S, Hasan T. Photodynamic and antibiotic therapy in combination
 against bacterial infections: efficacy, determinants, mechanisms, and future perspectives. *Advanced Drug Delivery Reviews.* 2021;177:113941.
- 452 11. Snell SB, Gill AL, Haidaris CG, Foster TH, Baran TM, Gill SR. Staphylococcus aureus Tolerance and
 453 Genomic Response to Photodynamic Inactivation. *mSphere*. 2021;6(1):e00762-00720.
- 454 12. Chan H, Pavelka MS, Baran TM. Methylene blue photodynamic therapy of bacterial species
 455 found in human abscesses: planktonic, biofilm, and 3D silicone models. Paper presented at:
 456 Proc.SPIE2023.
- 457 13. Yassine A-A, Lilge L, Betz V. Machine learning for real-time optical property recovery in
 458 interstitial photodynamic therapy: a stimulation-based study. *Biomed Opt Express.*459 2021;12(9):5401-5422.
- 460 14. Altschuler MD, Zhu TC, Li J, Hahn SM. Optimized interstitial PDT prostate treatment planning
 461 with the Cimmino feasibility algorithm. *Med Phys.* 2005;32(12):3524-3536.
- 462 15. Sandell JL, Zhu TC. A review of *in-vivo* optical properties of human tissues and its impact on PDT.
 463 *J Biophotonics*. 2011;4:773-787.
- 464 16. Quon H, Grossman CE, Finlay JC, et al. Photodynamic therapy in the management of pre465 malignant head and neck mucosal dysplasia and microinvasive carcinoma. *Photodiagnosis and*466 *Photodynamic Therapy*. 2011;8(2):75-85.
- 467 17. van Doeveren TEM, Bouwmans R, Wassenaar NPM, et al. On the Development of a Light
 468 Dosimetry Planning Tool for Photodynamic Therapy in Arbitrary Shaped Cavities: Initial Results.
 469 Photochemistry and Photobiology. 2020;96(2):405-416.
- 470 18. Staveren HJv, Beek JF, Ramaekers JWH, Keijzer M, Star WM. Integrating sphere effect in whole
 471 bladder wall photodynamic therapy: I. 532 nm versus 630 nm optical irradiation. *Phys Med Biol.*472 1994;39:947-959.

473	19.	Lilge L, Wu J, Xu Y, et al. Minimal required PDT light dosimetry for nonmuscle invasive bladder
474		cancer. Journal of Biomedical Optics. 2020;25(6):068001.
475	20.	Baran TM, Choi HW, Flakus MJ, Sharma AK. Photodynamic therapy of deep tissue abscess
476		cavities: Retrospective image-based feasibility study using Monte Carlo simulation. Med Phys.
477		2019;46:3259-3267.
478	21.	Li Z, Nguyen L, Bass DA, Baran TM. Effects of patient-specific treatment planning on eligibility for
479		photodynamic therapy of deep tissue abscess cavities: retrospective Monte Carlo simulation
480		study. Journal of Biomedical Optics. 2022;27(8):083007.
481	22.	Hannan MN, Sharma AK, Baran TM. Preliminary measurements of optical properties in human
482		abscess cavities prior to methylene blue photodynamic therapy. Paper presented at: Proc.
483		SPIE2023.
484	23.	Hannan MN, Sharma AK, Baran TM. First in human measurements of abscess cavity optical
485		properties and methylene blue uptake prior to photodynamic therapy by <i>in vivo</i> diffuse
486		reflectance spectroscopy. medRvix. 2023;2023.10.16.23297088.
487	24.	Bridger KG, Roccabruna JR, Baran TM. Optical property recovery with spatially-resolved diffuse
488		reflectance at short source-detector separations using a compact fiber-optic probe. <i>Biomed Opt</i>
489		Express. 2021:12(12):7388-7404.
490	25.	Baran TM. Foster TH. New Monte Carlo model of cylindrical diffusing fibers illustrates axially
491		heterogeneous fluorescence detection: simulation and experimental validation. <i>Journal of</i>
492		Biomedical Optics. 2011:16(8):085003.
493	26.	Genina EA. Bashkatov AN. Tuchin VV. In-vitro study of methylene blue diffusion through the skin
494	-	tissue. Paper presented at: Proc.SPIE2002.
495	27.	Bashkatov AN. Genina EA. Kochubev VI. et al. Optical properties of human maxillary sinus
496		mucosa and estimation of Methylene Blue diffusion coefficient in the tissue. Paper presented at:
497		Proc.SPIE2005.
498	28.	Kosarieh E. Bolhari B. Saniari Piravvatlou S. et al. Effect of Er:YAG laser irradiation using SWEEPS
499		and PIPS technique on dve penetration depth after root canal preparation. <i>Photodiagnosis and</i>
500		Photodynamic Therapy, 2021:33:102136.
501	29.	Wang Y. Li Y. Huang S. Huang J. Huang X. An easily achievable strategy to promote the
502	-	penetration of methylene blue into dentinal tubules. <i>Photodiaanosis and Photodynamic</i>
503		Therapy. 2023:41:103237.
504	30.	Wang H-W. Zhu TC. Putt MP. et al. Broadband reflectance measurements of light penetration.
505		blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal
506		tissues before and after photodynamic therapy. <i>Journal of Biomedical Optics</i> .
507		2005:10(1):014004.
508	31.	Staveren HJV, Moes CIM, Marle JV, Prahl SA, Gemert MICV, Light scattering in Intralipid-10% in
509		the wavelength range of 400-1100 nm. <i>Appl Opt</i> . 1991:30(31):4507-4514.
510	32	Nyst HL van Veen RLP. Tan IB. et al. Performance of a dedicated light delivery and dosimetry
511	02.	device for photodynamic therapy of pasopharyngeal carcinoma: Phantom and volunteer
512		experiments Lasers in Surgery and Medicine 2007:39(8):647-653
512	22	leries W. Unile T. Hamdoon 7. et al. Ultrasound-guided photodynamic therapy for deep seated
514	55.	nathologies: prospective study. Lasers in Surgery and Medicine. 2009-41(9)-612-621
515	34	Ouon H. Finlay I. Cengel K. Zhu T. O'Malley B. Weinstein G. Transoral robotic photodynamic
516	54.	therapy for the oronharypy Photodiagnosis and Photodynamic Therapy 2011;8(1):64-67
517	35	Friedberg IS Culligan MI Mick R et al. Radical Pleurectomy and Intraoperative Photodynamic
518	55.	Therapy for Malignant Pleural Mesothelioma. The Annals of Thoracic Surgery 2012;93(5):1658-
510		1667
515		1007.

520	36.	Zhu TC, Ong Y, Kim MM, et al. Evaluation of Light Fluence Distribution Using an IR Navigation
521		System for HPPH-mediated Pleural Photodynamic Therapy (pPDT). Photochemistry and
522		Photobiology. 2020;96(2):310-319.
523	37.	Yu L, Wu Y, Dunn JF, Murari K. In-vivo monitoring of tissue oxygen saturation in deep brain
524		structures using a single fiber optical system. <i>Biomed Opt Express.</i> 2016;7(11):4685-4694.
525	38.	Guirao X, García-Domingo M, Lladó L, et al. A New Model of Intraabdominal Abscess: Usefulness
526		for Hydrosaline Metabolism Studies in Parenteral Nutrition Associated with Sepsis. Journal of
527		Surgical Research. 1995;59(6):658-665.
528	39.	Sellera FP, Gargano RG, Libera AMMPD, et al. Antimicrobial photodynamic therapy for caseous
529		lymphadenitis abscesses in sheep: Report of ten cases. Photodiagnosis Photodyn Ther.
530		2016;13:120-122.
531	40.	Svaasand LO, Tromberg BJ, Wyss P, Wyss-Desserich MT, Tadir Y, Berns MW. Light and drug
532		distribution with topically administered photosensitizers. Lasers in Medical Science.
533		1996;11(4):261-265.
534	41.	Kosarieh E, Khavas SS, Rahimi A, Chiniforush N, Gutknecht N. The comparison of penetration
535		depth of two different photosensitizers in root canals with and without smear layer: An in vitro
536		study. Photodiagnosis and Photodynamic Therapy. 2016;13:10-14.
537	42.	Gerritsen MJP, Smits T, Kleinpenning MM, van de Kerkhof PCM, van Erp PEJ. Pretreatment to
538		Enhance Protoporphyrin IX Accumulation in Photodynamic Therapy. Dermatology.
539		2008;218(3):193-202.
540	43.	Johansson A, Axelsson J, Andersson-Engels S, Swartling J. Realtime light dosimetry software
541		tools for interstitial photodynamic therapy of the human prostate. Medical Physics.
542		2007;34(11):4309-4321.
543	44.	Fu R, Leader JK, Pradeep T, et al. Automated delineation of orbital abscess depicted on CT scan
544		using deep learning. Medical Physics. 2021;48(7):3721-3729.

545

546 Figure Captions

- 547 **Figure 1.** (a) Pre-procedure Computed Tomography (CT) image for a representative subject.
- 548 The margin of the segmented abscess area is shown in light blue. (b) Segmented abscess
- rendered in three dimensions (3D) for the same individual. (c) Threshold optical power as a
- 550 function of Intralipid concentration inside the abscess. The intersection of the red horizontal and
- vertical dashed lines indicates the optimal Intralipid concentration and corresponding optimal
- 552 optical power for this subject after treatment planning. (d) Dose volume histogram representing
- 553 coverage of the abscess wall as a function of fluence rate for the three simulated conditions.
- **Figure 2.** Percentage of the abscess wall that received a fluence rate above (a) 4 mW/cm² or
- (c) 20 mW/cm² under assumed, measured, and treatment planning cases for all 13 subjects.
- 556 Each color represents an individual subject. Corresponding means and standard deviations
- across subjects are included for the (c) 4 mW/cm² and (d) 20 mW/cm² cases. Percentage of the
- abscess wall that received a fluence rate above 400 mW/cm² for these three cases at
- 559 thresholds of (e) 4 mW/cm² and (f) 20 mW/cm². * p<0.05 ** p<0.01
- Figure 3. (a) Comparison of the optical power that was delivered clinically and optimal optical
 power determined by treatment planning for all 13 subjects. Each color represents an individual
 subject. (b) Corresponding means and standard deviations across subjects.
- **Figure 4.** Relationship between optical power required to achieve a fluence rate of 4 mW/cm² in 95% of the abscess wall after treatment planning and (a) abscess wall μ_a , or (b) abscess surface area, using flat cleaved fiber.
- 566 **Figure 5.** Comparison between flat-cleaved and spherical diffuser fibers for (a) optimal Intralipid
- 567 concentration and (b) required optical power after treatment planning. Corresponding means
- 568 and standard deviations are included for (c) optimal Intralipid concentration and (d) required
- 569 optical power. *** p<0.001
- 570 **Figure 6.** (a) Comparison of threshold optical power after treatment planning between flat
- 571 cleaved fibers and spherical diffuser fibers for the case of 0% Intralipid concentration with (b)
- 572 corresponding means and standard deviations across subjects. ** p<0.01